REDWOOD CITY, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that management will present at the following investor conferences: Wells Fargo Healthcare ConferenceFormat: Fireside Chat and 1x1 meetingsDate: Thursday, September 4 at 1:30 pm PT/ 4:30 pm ETLocation: Boston, MAWebcast Link: Click here Lake Street Best Ideas Growth (BIG9) ConferenceFormat: 1x1 meetingsDate ...

Company Overview - Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD) [2] - The company’s key products include the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Reports, which are designed for patients with severe emphysema/COPD [2] - The Zephyr Valve has received FDA pre-market approval and is recognized as a "breakthrough device," being commercially available in over 25 countries and included in global treatment guidelines [2] Upcoming Events - Pulmonx will present at the Canaccord Genuity 45th Annual Growth Conference in Boston on August 12, 2025, at 7:00 AM PT / 10:00 AM ET [1] - A live and archived webcast of the presentation will be accessible on the "Investors" section of the Pulmonx website [1]

Company Overview - Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD) [2] - The company’s key products include the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTrax™ Platform, and StratX Lung Analysis Reports, which are designed for patients with severe emphysema/COPD [2] - The Zephyr Valve has received FDA pre-market approval and is recognized as a "breakthrough device," being commercially available in over 25 countries and included in global treatment guidelines [2] Upcoming Events - Pulmonx will present at the Goldman Sachs 46th Annual Global Health Care Conference in Miami on June 11, 2025, at 7:00 AM PT / 10:00 AM ET [1] - A live and archived webcast of the presentation will be accessible on the "Investors" section of the Pulmonx website [1]

Core Insights - Pulmonx Corporation reported a strong start to 2025, emphasizing its strategy to expand patient access to Zephyr Valves and highlighting solid commercial performance [3][4]. Financial Performance - Total worldwide revenue for Q1 2025 was $22.5 million, a 20% increase from $18.9 million in Q1 2024, and a 21% increase on a constant currency basis [4][9]. - U.S. revenue reached $14.2 million, reflecting an 11% year-over-year increase, while international revenue was $8.3 million, marking a 39% increase compared to Q1 2024, and a 43% increase on a constant currency basis [4][9]. - Gross profit for Q1 2025 was $16.3 million, with a gross margin of 73%, down from 75% in the same period of 2024 [5][9]. - Operating expenses increased to $30.9 million, up 8% from $28.6 million in Q1 2024, primarily due to higher commercial investments [5][9]. - The net loss for Q1 2025 was $14.4 million, or $0.36 per share, compared to a net loss of $13.7 million, also $0.36 per share, in Q1 2024 [6][9]. 2025 Financial Outlook - The company reaffirmed its full-year 2025 revenue guidance, expecting it to be in the range of $96 million to $98 million, with a gross margin of approximately 74% [7][8]. - Total operating expenses for 2025 are anticipated to be between $133 million and $135 million, including about $22 million in non-cash stock-based compensation [7][8]. Recent Developments - Pulmonx amended its loan agreement with CIBC Innovation Banking to extend the interest-only period through October 2027 [9]. - The U.S. Department of Justice declined to intervene in a case against Pulmonx, concluding the civil investigative demand [9].